The purpose of the study is to learn if the study drug (CAEL-101) helps people with AL amyloidosis that has affected their hearts to live longer. CAEL-101 is a monoclonal antibody, which is made to bind to specific things in your body like the proteins that cause AL amyloidosis
COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4
North Carolina (Statewide)
Sascha Tuchman
LCCC - Clinical Trials
Clinical or Medical
Interventional
Blood Conditions
Cancer (Multiple Myeloma)
20-1713
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
